Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.
Hyman DM, Tran B, Paz-Ares L, Machiels JP, Schellens JH, Bedard PL, Campone M, Cassier PA, Sarantopoulos J, Vaishampayan U, Chugh R, Mahipal A, Lockhart AC, Sessa C, Zander T, Ng M, Curigliano G, Bendiske J, Chen X, Choudhury S, Graus-Porta D, Lewis N, Perez Garcia JM, de Miguel-Luken MJ.
Hyman DM, et al. Among authors: mahipal a.
JCO Precis Oncol. 2019 Dec;3:1-13. doi: 10.1200/PO.19.00221.
JCO Precis Oncol. 2019.
PMID: 35100734